The ICH M7 guideline establishes the international framework for controlling genotoxic impurities such as nitrosamines and NDSRIs in medical products.
Compliance requires risk assessment, strict limits, and highly sensitive analytical methods to ensure patient safety.
What are nitrosamines and why are they a concern?
Nitrosamines are chemical compounds formed when amines react with nitrosating agents. In the context of ICH M7, they are considered high-risk genotoxic impurities.
They can originate from:
- Active pharmaceutical ingredient (API) synthesis
- Manufacturing processes
- Raw material contamination
- Storage conditions
Many nitrosamines have carcinogenic potential, which has led to:
- Drug recalls (since 2018)
- Global review of manufacturing processes
- Stricter regulatory requirements
What are NDSRIs according to ICH M7?
NDSRIs (Nitrosamine Drug Substance-Related Impurities) are nitrosamines directly related to the structure of the active substance.
Key characteristics:
- Derived from the drug substance itself
- Specific to each API
- Typically lack commercial standards
- Require customized analytical methods
Under ICH M7, their evaluation involves:
- Structural analysis of the API
- Predictive formation studies
- Specific analytical method development
Role of the ICH M7 Guideline in impurity control
This guideline defines how to identify, assess, and limit mutagenic impurities.
Key concept: TTC (Threshold of Toxicological Concern)
- General value: 1.5 µg/day
- For nitrosamines: stricter limits
Fundamental principles of ICH M7:
- Risk-based approach
- Structured scientific evaluation
- Control throughout the entire product lifecycle
Analytical methods for nitrosamines and NDSRIs
Compliance with ICH M7 requires detection at extremely low levels (ppb).
Most commonly used techniques:
- LC-MS/MS (liquid chromatography–mass spectrometry)
- GC-MS (gas chromatography–mass spectrometry)
Analytical challenges:
- High sensitivity requirements
- Matrix interferences
- Lack of standards (especially for NDSRIs)
- Complex validation
Risk assessment according to ICH M7
Pharmaceutical companies apply systematic strategies to identify and control the potential formation of genotoxic impurities.
Risk analysis includes raw materials and reagents, solvents, process conditions, and possible side reactions that may promote nitrosamine formation.
It also evaluates manufacturing process design, packaging, and storage conditions, as well as the potential presence of amines or nitrosating agents at any stage of the product lifecycle.
Regulatory impact and future challenges
The implementation of the guideline has led to a profound shift in how the pharmaceutical industry approaches the control of genotoxic impurities.
Key changes include increased analytical requirements, higher control costs, and the need for highly specialized technical expertise.
Looking ahead, challenges include developing specific methods for NDSRIs, achieving global regulatory harmonization, and improving predictive models to anticipate the formation of these impurities.
Frequently Asked Questions
- What does ICH M7 regulate?
ICH M7 regulates the evaluation and control of genotoxic impurities in pharmaceuticals to minimize carcinogenic risk. - Why are nitrosamines critical?
Because many exhibit high carcinogenic potency even at very low levels. - What is the difference between nitrosamines and NDSRIs?
NDSRIs are directly related to the active substance, whereas other nitrosamines may originate from external contaminants. - What techniques are used for their analysis?
Primarily LC-MS/MS and GC-MS due to their high sensitivity. - What is TTC in ICH M7?
It is the toxicological threshold that defines a daily exposure considered low risk (generally 1.5 µg/day).
